[
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/sponsored/agentic-ai-can-fix-healthcares-communications-crisis-heres-how\" hreflang=\"en\">Agentic AI can fix healthcare’s communications crisis – here’s how</a>",
    "summary": "```json\n{\n  \"summary\": \"This is a sponsored content piece discussing how agentic AI technology can address communication challenges in healthcare settings. The article suggests that poor communication",
    "url": "https://www.fiercepharma.com/sponsored/agentic-ai-can-fix-healthcares-communications-crisis-heres-how",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/sponsored/data-decisions-how-walgreens-powering-smarter-pharma-strategies\" hreflang=\"en\">From data to decisions: how Walgreens is powering smarter pharma strategies</a>",
    "summary": "```json\n{\n  \"summary\": \"Walgreens is leveraging retail pharmacy data insights to help pharmaceutical companies identify patient barriers and improve medication access and adherence. The initiative aim",
    "url": "https://www.fiercepharma.com/sponsored/data-decisions-how-walgreens-powering-smarter-pharma-strategies",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/fierce-pharma-regulatory-tracker-second-half-2025\" hreflang=\"en\">Regulatory tracker: Agios awaits FDA decision as target date passes</a>",
    "summary": "```json\n{\n  \"summary\": \"Fierce Pharma is tracking regulatory progress of in-market products, including geographic expansions and new indications. Agios is awaiting an FDA decision that has passed its ",
    "url": "https://www.fiercepharma.com/pharma/fierce-pharma-regulatory-tracker-second-half-2025",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [
      "PAS"
    ],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/ash-regeneron-does-subtraction-bids-move-bispecifics-earlier-treatment-blood-cancers\" hreflang=\"en\">ASH: Regeneron eyes simpler regimens in bid to move bispecifics into earlier blood cancer treatment</a>",
    "summary": "```json\n{\n  \"summary\": \"Regeneron is working to advance its T-cell engager bispecific antibodies Lynozyfic and Ordspono into earlier lines of blood cancer treatment. The company's strategy focuses on ",
    "url": "https://www.fiercepharma.com/pharma/ash-regeneron-does-subtraction-bids-move-bispecifics-earlier-treatment-blood-cancers",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/sponsored/how-one-companys-focus-patient-journey-fuels-innovation-across-spectrum-medicine\" hreflang=\"en\">Beyond the treatment: Innovation on the human side of medicine</a>",
    "summary": "```json\n{\n  \"summary\": \"This is a sponsored content piece discussing how a pharmaceutical company is focusing on understanding the patient journey to improve healthcare accessibility and innovation. T",
    "url": "https://www.fiercepharma.com/sponsored/how-one-companys-focus-patient-journey-fuels-innovation-across-spectrum-medicine",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/manufacturing/cuban-tells-trump-waiving-fda-approval-fees-would-spur-generics-manufacturing-us\" hreflang=\"en\">Lowering FDA fees would spur generics manufacturing in US, Mark Cuban says</a>",
    "summary": "```json\n{\n  \"summary\": \"Mark Cuban, co-founder of Cost Plus Drugs, stated that his online pharmacy company would manufacture generic drugs in the United States if the FDA eliminated approval fees. Cub",
    "url": "https://www.fiercepharma.com/manufacturing/cuban-tells-trump-waiving-fda-approval-fees-would-spur-generics-manufacturing-us",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/ash-csl-proves-hemophilia-b-gene-therapy-hemgenix-holds-after-5-years-post-dosing\" hreflang=\"en\">ASH: CSL proves efficacy of hemophilia B gene therapy Hemgenix holds up after 5 years</a>",
    "summary": "```json\n{\n  \"summary\": \"CSL reported 5-year follow-up data from its Hope-B study showing that Hemgenix, a one-time gene therapy for hemophilia B, reduced annualized bleeding rates by 90% by the fifth ",
    "url": "https://www.fiercepharma.com/pharma/ash-csl-proves-hemophilia-b-gene-therapy-hemgenix-holds-after-5-years-post-dosing",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/ash-pfizer-aiming-level-hemophilia-playing-field-trots-out-hympavzi-inhibitors-data\" hreflang=\"en\">ASH: Pfizer, aiming to level the hemophilia playing field, trots out new Hympavzi data</a>",
    "summary": "```json\n{\n  \"summary\": \"Pfizer presented new phase 3 data for its hemophilia drug Hympavzi at the ASH conference. The data is positioned to help Hympavzi compete with rival hemophilia treatments from ",
    "url": "https://www.fiercepharma.com/pharma/ash-pfizer-aiming-level-hemophilia-playing-field-trots-out-hympavzi-inhibitors-data",
    "date": "2025-12-08",
    "companies_detected": [
      "Novo Nordisk",
      "Pfizer",
      "Sanofi"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/marketing/abbvie-revs-skyrizi-spending-top-tv-ad-totals-november-edging-out-jjs-tremfya\" hreflang=\"en\">AbbVie revs up Skyrizi spending to top TV ad totals in November, edging out J&amp;J's Tremfya</a>",
    "summary": "```json\n{\n  \"summary\": \"AbbVie led pharmaceutical TV advertising spending in November with its drug Skyrizi, narrowly surpassing Johnson & Johnson's Tremfya. This followed a record-setting October for",
    "url": "https://www.fiercepharma.com/marketing/abbvie-revs-skyrizi-spending-top-tv-ad-totals-november-edging-out-jjs-tremfya",
    "date": "2025-12-08",
    "companies_detected": [
      "AbbVie"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/cdcs-acip-votes-tweak-long-standing-hepatitis-b-vaccine-guidance-infants-prompting-backlash\" hreflang=\"en\">CDC's ACIP votes to change longstanding hepatitis B vaccine guidance for newborns, prompting backlash </a>",
    "summary": "```json\n{\n  \"summary\": \"The CDC's Advisory Committee on Immunization Practices (ACIP) voted 8-2 to change the longstanding guidance for hepatitis B vaccination at birth, moving to an individual-based ",
    "url": "https://www.fiercepharma.com/pharma/cdcs-acip-votes-tweak-long-standing-hepatitis-b-vaccine-guidance-infants-prompting-backlash",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/biotech/unprecedented-turmoil-engulfing-fda-threatens-public-health-mrna-coalition-speaks-out\" hreflang=\"en\">'Unprecedented turmoil' engulfing FDA threatens public health: mRNA coalition speaks out</a>",
    "summary": "```json\n{\n  \"summary\": \"An mRNA industry coalition has issued a statement expressing concern about ongoing turmoil at the FDA, warning that instability in agency leadership is undermining public trust",
    "url": "https://www.fiercepharma.com/biotech/unprecedented-turmoil-engulfing-fda-threatens-public-health-mrna-coalition-speaks-out",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/marketing/avalere-health-hires-sarah-hall-lead-us-marketing-team-through-politically-dynamic-period\" hreflang=\"en\">Avalere Health hires Sarah Hall to lead US marketing team through 'politically dynamic' period</a>",
    "summary": "```json\n{\n  \"summary\": \"Avalere Health has appointed Sarah Hall as president of U.S. marketing to lead the company's marketing team. Hall is a direct-to-consumer expert who will guide the organization",
    "url": "https://www.fiercepharma.com/marketing/avalere-health-hires-sarah-hall-lead-us-marketing-team-through-politically-dynamic-period",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/fda-safety-probe-takeda-drug-otsuka-kidney-disease-nod-adc-patent-fight\" hreflang=\"en\">Fierce Pharma Asia—FDA safety probe of Takeda drug; Otsuka kidney disease nod; ADC patent fight</a>",
    "summary": "```json\n{\n  \"summary\": \"The FDA is investigating a safety signal related to Takeda's rare disease medication Adzynma. Otsuka received first-in-class FDA approval for an IgA nephropathy treatment. Daii",
    "url": "https://www.fiercepharma.com/pharma/fda-safety-probe-takeda-drug-otsuka-kidney-disease-nod-adc-patent-fight",
    "date": "2025-12-08",
    "companies_detected": [
      "Pfizer"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/mercks-keytruda-sc-launch-germany-faces-new-hurdle-halozyme-scores-preliminary-injunction\" hreflang=\"en\">Merck's Keytruda SC launch in Germany faces new hurdle as Halozyme scores preliminary injunction</a>",
    "summary": "```json\n{\n  \"summary\": \"Halozyme has obtained a preliminary injunction in Germany against Merck & Co., halting the launch of Keytruda SC (subcutaneous formulation) in the country. This represents prog",
    "url": "https://www.fiercepharma.com/pharma/mercks-keytruda-sc-launch-germany-faces-new-hurdle-halozyme-scores-preliminary-injunction",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/bms-scores-5th-indication-breyanzi-fda-marginal-zone-lymphoma-nod\" hreflang=\"en\">BMS scores 5th indication for Breyanzi with FDA marginal zone lymphoma nod</a>",
    "summary": "```json\n{\n  \"summary\": \"Bristol Myers Squibb's Breyanzi has received FDA approval for its fifth indication, marginal zone lymphoma, making it the first CAR-T therapy approved for this indication. This",
    "url": "https://www.fiercepharma.com/pharma/bms-scores-5th-indication-breyanzi-fda-marginal-zone-lymphoma-nod",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/marketing/pfizer-gsk-shionogi-sponsor-london-run-musical-about-antimicrobial-resistance\" hreflang=\"en\">Pfizer, GSK, Shionogi sponsor London run of musical about antimicrobial resistance</a>",
    "summary": "```json\n{\n  \"summary\": \"Pfizer, GSK, and Shionogi are sponsoring a London musical production focused on raising awareness about antimicrobial resistance. The three pharmaceutical companies are support",
    "url": "https://www.fiercepharma.com/marketing/pfizer-gsk-shionogi-sponsor-london-run-musical-about-antimicrobial-resistance",
    "date": "2025-12-08",
    "companies_detected": [
      "Pfizer"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/fda-churn-and-burn-continues-departure-10-year-director-office-nonprescription-drugs\" hreflang=\"en\">FDA leadership churn continues with transfer of OTC drug office director</a>",
    "summary": "```json\n{\n  \"summary\": \"Theresa Michele, who served as director of the FDA's Office of Nonprescription Drugs for ten years, has been transferred to another role within the agency. This move continues ",
    "url": "https://www.fiercepharma.com/pharma/fda-churn-and-burn-continues-departure-10-year-director-office-nonprescription-drugs",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/marketing/daiichi-sankyo-receives-fda-untitled-letter-taking-aim-turalio-patient-ambassador-video\" hreflang=\"en\">Daiichi Sankyo receives FDA untitled letter taking aim at Turalio patient ambassador video</a>",
    "summary": "```json\n{\n  \"summary\": \"The FDA's Office of Prescription Drug Promotion issued an untitled letter to Daiichi Sankyo regarding promotional concerns with a patient testimonial video for Turalio. The let",
    "url": "https://www.fiercepharma.com/marketing/daiichi-sankyo-receives-fda-untitled-letter-taking-aim-turalio-patient-ambassador-video",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/biopharma-dealmaking-landscape-and-what-expect-2026\" hreflang=\"en\">The biopharma dealmaking landscape and what to expect in 2026</a>",
    "summary": "",
    "url": "https://www.fiercepharma.com/pharma/biopharma-dealmaking-landscape-and-what-expect-2026",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/former-fda-commissioners-blast-prasad-proposed-vaccine-policy-changes\" hreflang=\"en\">A dozen former FDA commissioners blast Prasad's proposed vaccine policy changes</a>",
    "summary": "```json\n{\n  \"summary\": \"Twelve former FDA commissioners have publicly criticized proposed vaccine policy changes put forward by top FDA official Vinay Prasad, M.D. The former commissioners are pushing",
    "url": "https://www.fiercepharma.com/pharma/former-fda-commissioners-blast-prasad-proposed-vaccine-policy-changes",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/cdcs-acip-pushes-back-planned-vote-infant-hepatitis-b-vaccines-confusion-debate-abounds\" hreflang=\"en\">CDC's ACIP pushes back planned vote on newborn hepatitis B vaccines as confusion, debate abound</a>",
    "summary": "",
    "url": "https://www.fiercepharma.com/pharma/cdcs-acip-pushes-back-planned-vote-infant-hepatitis-b-vaccines-confusion-debate-abounds",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/cosmo-shares-zoom-results-2-male-pattern-hair-loss-trials\" hreflang=\"en\">Cosmo shares zoom with results from 2 male-pattern hair loss trials</a>",
    "summary": "```json\n{\n  \"summary\": \"Cosmo Pharmaceuticals announced topline results from two phase 3 trials evaluating clascoterone, a topical cream for male-pattern hair loss. The results suggest the treatment c",
    "url": "https://www.fiercepharma.com/pharma/cosmo-shares-zoom-results-2-male-pattern-hair-loss-trials",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/manufacturing/quvara-medical-debuts-newest-cdmo-after-group-buys-becton-dickinson-facility\" hreflang=\"en\">Quvara Medical debuts as latest CDMO after Buckland Group buys Becton Dickinson facility</a>",
    "summary": "```json\n{\n  \"summary\": \"The Buckland Group has launched Quvara Medical as a new contract development and manufacturing organization (CDMO) following the acquisition of a former Becton Dickinson manufa",
    "url": "https://www.fiercepharma.com/manufacturing/quvara-medical-debuts-newest-cdmo-after-group-buys-becton-dickinson-facility",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/biotech/fda-names-tracy-beth-hoeg-fresh-vaccine-safety-probe-acting-head-drug-center\" hreflang=\"en\">FDA names Tracy Beth Høeg, fresh from vaccine safety probe, as acting head of drug center</a>",
    "summary": "",
    "url": "https://www.fiercepharma.com/biotech/fda-names-tracy-beth-hoeg-fresh-vaccine-safety-probe-acting-head-drug-center",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/dyne-readies-fda-push-after-dmd-exon-51-med-excels-trial\" hreflang=\"en\">Dyne readies FDA push after DMD exon 51 med excels in trial</a>",
    "summary": "```json\n{\n  \"summary\": \"Dyne Therapeutics is preparing to submit an FDA application for its exon 51 skipping therapy for Duchenne muscular dystrophy (DMD) after positive trial results. CEO John Cox st",
    "url": "https://www.fiercebiotech.com/biotech/dyne-readies-fda-push-after-dmd-exon-51-med-excels-trial",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercepharma",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercepharma.com/pharma/after-dodging-biosecure-threat-wuxi-apptec-pentagons-crosshairs\" hreflang=\"en\">After dodging Biosecure threat, WuXi AppTec faces new security scrutiny from Pentagon: Bloomberg</a>",
    "summary": "",
    "url": "https://www.fiercepharma.com/pharma/after-dodging-biosecure-threat-wuxi-apptec-pentagons-crosshairs",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [
      "XTEN"
    ],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/mirum-nets-bluejay-and-its-phase-3-stage-hepatitis-drug-620m\" hreflang=\"en\">Mirum beckons Bluejay and its phase 3-stage hepatitis drug for $620M</a>",
    "summary": "```json\n{\n  \"summary\": \"Mirum Pharmaceuticals is acquiring Bluejay Therapeutics for $620 million in cash and stock. The acquisition includes Bluejay's phase 3-stage hepatitis drug candidate.\",\n  \"even",
    "url": "https://www.fiercebiotech.com/biotech/mirum-nets-bluejay-and-its-phase-3-stage-hepatitis-drug-620m",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/wave-structure-move-assets-clinical-ladder-biotechs-obesity-development-blitz-rolls\" hreflang=\"en\">Wave, Structure stocks double on obesity data readouts</a>",
    "summary": "```json\n{\n  \"summary\": \"Wave Life Sciences and Structure Therapeutics reported obesity data that caused their stock prices to double in early trading. Both biotechnology companies are competing in the",
    "url": "https://www.fiercebiotech.com/biotech/wave-structure-move-assets-clinical-ladder-biotechs-obesity-development-blitz-rolls",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/dr-reddys-pens-370m-pact-rights-immuteps-phase-3-stage-immunotherapy-certain-markets\" hreflang=\"en\">Dr. Reddy's pens $370M pact for rights to Immutep's phase 3-stage immunotherapy in certain markets </a>",
    "summary": "```json\n{\n  \"summary\": \"Dr. Reddy's Laboratories has entered into a $370 million deal with Immutep, paying $20 million upfront for rights to Immutep's phase 3-stage LAG-3 immunotherapy candidate in ce",
    "url": "https://www.fiercebiotech.com/biotech/dr-reddys-pens-370m-pact-rights-immuteps-phase-3-stage-immunotherapy-certain-markets",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/sponsored/agc-biologics-leader-warns-looming-microbial-manufacturing-crunch\" hreflang=\"en\">Is biopharma facing a microbial manufacturing crunch?</a>",
    "summary": "```json\n{\n  \"summary\": \"AGC Biologics' Dieter Kramer discusses the increasing demand for late-phase microbial manufacturing capacity in the biopharma industry. The article presents insights, data, and",
    "url": "https://www.fiercebiotech.com/sponsored/agc-biologics-leader-warns-looming-microbial-manufacturing-crunch",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/medtech/stryker-promotes-stiles-president-coo-lead-its-ma-growth-strategy\" hreflang=\"en\">Stryker promotes new president, COO to help lead its M&amp;A strategy</a>",
    "summary": "```json\n{\n  \"summary\": \"Stryker has promoted Spencer Stiles, a 27-year veteran of the company, to the positions of president and chief operating officer. This leadership change is aimed at supporting ",
    "url": "https://www.fiercebiotech.com/medtech/stryker-promotes-stiles-president-coo-lead-its-ma-growth-strategy",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/chinas-ascletis-reports-77-weight-loss-oral-glp-1-contender-us-phase-2-study\" hreflang=\"en\">China's Ascletis reports 7.7% weight loss for oral GLP-1 contender in US phase 2 study</a>",
    "summary": "```json\n{\n  \"summary\": \"Ascletis Pharma reported 7.7% weight loss results for the highest dose of its oral GLP-1 candidate in a US Phase 2 study. The company is competing in the highly contested oral ",
    "url": "https://www.fiercebiotech.com/biotech/chinas-ascletis-reports-77-weight-loss-oral-glp-1-contender-us-phase-2-study",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/sponsored/new-era-parkinsons-solengepras-leads-shift-beyond-dopamine\" hreflang=\"en\">A New Era in Parkinson’s: Solengepras Leads the Shift Beyond Dopamine</a>",
    "summary": "",
    "url": "https://www.fiercebiotech.com/sponsored/new-era-parkinsons-solengepras-leads-shift-beyond-dopamine",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/biontechs-ctla-4-drug-improves-survival-phase-3-cancer-trial-poses-tolerability-challenge\" hreflang=\"en\">BioNTech's CTLA-4 drug improves survival in phase 3 cancer trial but poses tolerability challenge</a>",
    "summary": "```json\n{\n  \"summary\": \"BioNTech and OncoC4's anti-CTLA-4 antibody demonstrated improved survival in a phase 3 cancer trial. However, detailed analysis of the data revealed significant tolerability ch",
    "url": "https://www.fiercebiotech.com/biotech/biontechs-ctla-4-drug-improves-survival-phase-3-cancer-trial-poses-tolerability-challenge",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/research/amphistas-targeted-glue-sticks-landing-aml-test-supporting-push-clinic\" hreflang=\"en\">Amphista's targeted glue sticks the landing in AML test, supporting push into the clinic</a>",
    "summary": "```json\n{\n  \"summary\": \"Amphista Therapeutics reported positive preclinical data for its protein degrader in acute myeloid leukemia (AML). The company, which has Big Pharma partnerships, is targeting ",
    "url": "https://www.fiercebiotech.com/research/amphistas-targeted-glue-sticks-landing-aml-test-supporting-push-clinic",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/ash-star-antibody-sparkles-preview-potential-phase-3-bleeding-disease-success\" hreflang=\"en\">ASH: Star antibody sparkles in preview of potential phase 3 bleeding disease success</a>",
    "summary": "```json\n{\n  \"summary\": \"Star Therapeutics presented encouraging phase 1/2 results for VGA039, an anti-bleeding antibody, at ASH in Orlando. The company has already initiated dosing in a pivotal phase ",
    "url": "https://www.fiercebiotech.com/biotech/ash-star-antibody-sparkles-preview-potential-phase-3-bleeding-disease-success",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/sponsored/how-ai-and-real-world-evidence-are-powering-smarter-decisions-across-drug-and-device\" hreflang=\"en\">How AI and real-world evidence are powering smarter decisions across the drug and device development lifecycle</a>",
    "summary": "",
    "url": "https://www.fiercebiotech.com/sponsored/how-ai-and-real-world-evidence-are-powering-smarter-decisions-across-drug-and-device",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/ash-anito-cel-strengthens-best-class-potential-kite-preps-launch\" hreflang=\"en\">ASH: Anito-cel strengthens best-in-class potential as Gilead's Kite preps for launch</a>",
    "summary": "",
    "url": "https://www.fiercebiotech.com/biotech/ash-anito-cel-strengthens-best-class-potential-kite-preps-launch",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/abbvie-hands-back-phase-1-duties-chronic-inflammation-drug-partner-ose\" hreflang=\"en\">AbbVie hands back phase 1 duties for chronic inflammation drug to partner Ose</a>",
    "summary": "",
    "url": "https://www.fiercebiotech.com/biotech/abbvie-hands-back-phase-1-duties-chronic-inflammation-drug-partner-ose",
    "date": "2025-12-08",
    "companies_detected": [
      "AbbVie"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/medtech/fda-panel-votes-against-jjs-novel-shunt-implant-heart-failure\" hreflang=\"en\">FDA panel votes against J&amp;J's novel shunt implant for heart failure</a>",
    "summary": "",
    "url": "https://www.fiercebiotech.com/medtech/fda-panel-votes-against-jjs-novel-shunt-implant-heart-failure",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/unprecedented-turmoil-engulfing-fda-threatens-public-health-mrna-coalition-speaks-out\" hreflang=\"en\">'Unprecedented turmoil' engulfing FDA threatens public health: mRNA coalition speaks out</a>",
    "summary": "",
    "url": "https://www.fiercebiotech.com/biotech/unprecedented-turmoil-engulfing-fda-threatens-public-health-mrna-coalition-speaks-out",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/encoded-deciphers-path-pivotal-trial-phase-12-dravet-gene-therapy-data\" hreflang=\"en\">Encoded deciphers path to pivotal trial with phase 1/2 Dravet gene therapy data</a>",
    "summary": "",
    "url": "https://www.fiercebiotech.com/biotech/encoded-deciphers-path-pivotal-trial-phase-12-dravet-gene-therapy-data",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/medtech/natera-buys-foresight-diagnostics-cancer-mrd-deal-worth-450m\" hreflang=\"en\">Natera buys Foresight Diagnostics in cancer testing deal worth up to $450M</a>",
    "summary": "",
    "url": "https://www.fiercebiotech.com/medtech/natera-buys-foresight-diagnostics-cancer-mrd-deal-worth-450m",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/markets-thinking-backwards-fdas-1-trial-approval-plan-would-boost-rd-spend-jefferies\" hreflang=\"en\">'Market's thinking is backwards': FDA's 1-trial approval plan would boost R&amp;D spend, Jefferies says</a>",
    "summary": "",
    "url": "https://www.fiercebiotech.com/biotech/markets-thinking-backwards-fdas-1-trial-approval-plan-would-boost-rd-spend-jefferies",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/medtech/cancer-blood-test-developer-freenome-go-public-330m-spac-deal\" hreflang=\"en\">Cancer blood test developer Freenome to go public in $330M SPAC deal</a>",
    "summary": "",
    "url": "https://www.fiercebiotech.com/medtech/cancer-blood-test-developer-freenome-go-public-330m-spac-deal",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/praxis-claims-efficacy-success-phase-2-seizure-trial-setting-approval-talks-fda\" hreflang=\"en\">Praxis claims efficacy success in phase 2 seizure trial, setting up approval talks with FDA</a>",
    "summary": "```json\n{\n  \"summary\": \"Praxis Precision Medicines reported positive efficacy results from a phase 2 clinical trial of its sodium channel inhibitor for treating seizures. The company plans to use this",
    "url": "https://www.fiercebiotech.com/biotech/praxis-claims-efficacy-success-phase-2-seizure-trial-setting-approval-talks-fda",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/chutes-ladders-yet-another-cder-leadership-shakeup\" hreflang=\"en\">Chutes &amp; Ladders—Yet another CDER leadership shake-up</a>",
    "summary": "```json\n{\n  \"summary\": \"The FDA's Center for Drug Evaluation and Research (CDER) is experiencing significant leadership turnover during President Trump's second term. Richard Pazdur, M.D., filed retir",
    "url": "https://www.fiercebiotech.com/biotech/chutes-ladders-yet-another-cder-leadership-shakeup",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/fierce-biotech-fundraising-tracker-25\" hreflang=\"en\">Fierce Biotech Fundraising Tracker '25: Triana glues together $120M series B; SciNeuro snags $53M</a>",
    "summary": "```json\n{\n  \"summary\": \"Fierce Biotech's 2025 fundraising tracker reports on venture capital rounds of $50 million or more in the biotech sector. Triana secured a $120 million Series B financing round",
    "url": "https://www.fiercebiotech.com/biotech/fierce-biotech-fundraising-tracker-25",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/biotech/pfizer-ventures-gets-behind-chinese-biotechs-100m-series-boost-rd-hubs-capability\" hreflang=\"en\">Pfizer Ventures gets behind Chinese biotech's $100M series A to boost R&amp;D hub's capability</a>",
    "summary": "",
    "url": "https://www.fiercebiotech.com/biotech/pfizer-ventures-gets-behind-chinese-biotechs-100m-series-boost-rd-hubs-capability",
    "date": "2025-12-08",
    "companies_detected": [
      "Pfizer"
    ],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  },
  {
    "source_key": "press_sector__fiercebiotech",
    "source_type": "press_sector",
    "title": "<a href=\"https://www.fiercebiotech.com/cro/paradigm-health-raises-78m-revamp-clinical-research-process-inks-deal-roches-flatiron\" hreflang=\"en\">Paradigm Health raises $78M to revamp clinical research process, inks deal with Roche's Flatiron</a>",
    "summary": "",
    "url": "https://www.fiercebiotech.com/cro/paradigm-health-raises-78m-revamp-clinical-research-process-inks-deal-roches-flatiron",
    "date": "2025-12-08",
    "companies_detected": [],
    "molecules_detected": [],
    "technologies_detected": [],
    "indications_detected": [],
    "event_type": "other"
  }
]